Hyaluronidase

Generic Name: Hyaluronidase

Brand Names: Amphadase

Drug Type: Biotech

CAS Number: 9001-54-1

Unique Ingredient Identifier: 8KOG53Z5EM

Background: Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.

Hyaluronidase was first used in prescription products in the United States on 5 May 2004.

Indication: Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography. Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.

Associated Therapies: Parenteral rehydration therapy, Parenteral drug administration, Subcutaneous urography

Clinical Trials

Effect of Hyaluronidase in Different Doses Added to Bupivacaine on TAB Block Quality During CS

Early Phase 1

Not yet recruiting

Conditions: Tab Block Qaulity

Interventions: Drug: Hyaluronidase

First Posted Date: 2025-02-21

Last Posted Date: 2025-02-21

Lead Sponsor: Benha University

Target Recruit Count: 120

Registration Number: NCT06839391

Myofascial Dysfunction in Post Stroke Shoulder Pain

Phase 2

Recruiting

Conditions: Stroke

Interventions: Drug: hyaluronidase plus saline
Drug: saline

First Posted Date: 2024-12-05

Last Posted Date: 2025-04-03

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 68

Registration Number: NCT06718413

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Hyaluronidase Assisted Subcutaneous Infusion

Phase 3

Completed

Conditions: Healthy

Interventions: Drug: hyaluronidase
Drug: Placebo

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Shanghai Bao Pharmaceuticals Co., Ltd.

Target Recruit Count: 45

Registration Number: NCT06604546

Locations: 🇨🇳
Suzhou Municipal Hospital, Su Zhou, Jiangsu, China

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

Not Applicable

Recruiting

Conditions: Amyloid Light-chain Amyloidosis

Interventions: Drug: Daratumumab/daratumumab and hyaluronidase-fihj
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2024-06-12

Last Posted Date: 2024-06-12

Lead Sponsor: Yongyong MA

Target Recruit Count: 20

Registration Number: NCT06455748

Locations: 🇨🇳
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

Daratumumab for Patients With Light Chain Amyloidosis

Not Applicable

Recruiting

Conditions: Light Chain (AL) Amyloidosis

Interventions: Drug: Dratumumab / Hyaluronidase Injection [Darzalex Faspro]
Drug: Pomalidomide 4 MG
Procedure: autologous stem cell transplantation (ASCT)

First Posted Date: 2024-04-19

Last Posted Date: 2024-04-19

Lead Sponsor: Nanjing University School of Medicine

Target Recruit Count: 100

Registration Number: NCT06376214

Locations: 🇨🇳
National Clinical Research Center for Kidney Diseases, Jinling Hospital, Nanjing, Jiangsu, China

Hyaluronidase Via LADD Scleroderma-induced Microstomia

Early Phase 1

Completed

Conditions: Microstomia
Scleroderma

Interventions: Drug: Hyaluronidase
Device: CO2 laser

First Posted Date: 2023-08-16

Last Posted Date: 2025-04-13

Lead Sponsor: University of Nebraska

Target Recruit Count: 3

Registration Number: NCT05995626

Locations: 🇺🇸
University of Nebraska Medical Center, Lauritzen Outpatient Center, Omaha, Nebraska, United States
🇺🇸
Nebraska Medicine, Dermatology Westroads, Omaha, Nebraska, United States